GlobeNewswire
-
Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum
15/06/2026 -
Intravacc and SynphaBase Announce Strategic Partnership to Advance Conjugate Vaccine Development
15/06/2026 -
Aerska Strengthens Board with Appointments of Uli Stilz and Itziar Canamasas
15/06/2026 -
Reunion Neuroscience Announces Appointment of Sahil V. Kirpekar, M.D., as President and CEO
15/06/2026 -
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
15/06/2026 -
Immuneering Appoints Andrew Gengos as Chief Financial Officer
15/06/2026 -
10 Barrel Brewing and Pub Beer Kick Off Pacific Northwest Summer of Soccer Celebration
15/06/2026 -
BioSyent to Present at Planet MicroCap Las Vegas
15/06/2026 -
SafeSpace Global Appoints Michael Hrynuik as Chief Financial Officer
15/06/2026 -
InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition
15/06/2026 -
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
15/06/2026 -
AI is changing what is possible in the $10 trillion food industry. Anterra Capital is backing what comes next.
15/06/2026 -
ProSomnus® Sleep Technologies and MonitAir® Announce Collaboration to Enhance Connected Care for Obstructive Sleep Apnea
15/06/2026 -
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
15/06/2026 -
XBiotech lance un essai clinique de phase II visant à évaluer le vilamakitug dans le traitement de la spondylarthrite axiale active
15/06/2026 -
BVI Expands Commitment to Ophthalmic Education with New Experience Hub in Europe
15/06/2026 -
Cuprina Receives U.S. FDA 510(k) Clearance for MEDIFLY Maggots — the First U.S. Clearance for a Lucilia cuprina Maggot Debridement Product
15/06/2026 -
Cosmos Health Provides Update on United States Portfolio; Four 18 Series Products Introduced With Projected Annualized Revenue Over $22.7M and Approximately $17.0M Gross Profit
15/06/2026 -
Cannabix Technologies Announces Deployment of Marijuana Breath Test (MBT) with Major Industrial Operator in Quebec
15/06/2026
Pages